HAIC Combined With Toripalimab and Donafenib for Advanced BTC
This is a single center, single arm, phase II, prospective study to evaluate the efficacy and safety of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with PD-1 inhibitor immunotherapy Toripalimab and Tyrosine Kinase Inhibitor Donafenib in patients with advanced biliary tract cancer.
Biliary Tract Adenocarcinoma
PROCEDURE: HAIC|DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Toripalimab|DRUG: Donafenib
Objective response rate (ORR), the sum of complete response rate and partial response rate, through study completion, an average of 2 year
Disease Control rate (DCR), the sum of complete response rate, partial response rate and stable disease rate, through study completion, an average of 2 year|Progression-free survival (PFS), Time from randomization to disease progression, through study completion, an average of 2 year|Overall survival (OS), Time from randomization to death for any cause, through study completion, an average of 2 year|Number of participants with treatment-related adverse events as assessed by NCI CTCAE v4.0., Unforeseen medical events occurred when the subjects received drug treatment or research, but there is not necessarily a causal relationship with the drugs used.

Severe adverse events, through study completion, an average of 2 year|Quality of life questionnaire, The concept of comprehensively evaluating the quality of life, through study completion, an average of 2 year
This is a single center, single arm, phase II, prospective study to evaluate the efficacy and safety of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with PD-1 inhibitor immunotherapy Toripalimab and Tyrosine Kinase Inhibitor Donafenib in patients with advanced biliary tract cancer.